Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis
Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...
Aileron Therapeutics Reports Positive Phase 1b Data Of LTI-03 In Idiopathic Pulmonary Fibrosis
(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
You should be paying more attention to your lungs. KU Med is helping you do it | Opinion
Survival rates for idiopathic pulmonary fibrosis are worse than all solid cancers except for lung and pancreatic cancer. | ...
GEN1d
Insilico Plans Pivotal Trial for AI-Based IPF Candidate
The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...